Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition (Q39961053)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition (English)

1 reference

Europe PubMed Central

15 September 2017

3

1 reference

Europe PubMed Central

15 September 2017

7

object named as

Florian Hohla

1 reference

Europe PubMed Central

15 September 2017

4

object named as

Arnd Hönig

1 reference

Europe PubMed Central

15 September 2017

author name string

Frank Köster

1

1 reference

Europe PubMed Central

15 September 2017

Jörg B Engel

2

1 reference

Europe PubMed Central

15 September 2017

Andreas Schröer

5

1 reference

Europe PubMed Central

15 September 2017

Stephan Seitz

6

1 reference

Europe PubMed Central

15 September 2017

Olaf Ortmann

8

1 reference

Europe PubMed Central

15 September 2017

Klaus Diedrich

9

1 reference

Europe PubMed Central

15 September 2017

Stefan Buchholz

10

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

16 July 2008

1 reference

Europe PubMed Central

15 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

15 September 2017

116

1 reference

Europe PubMed Central

15 September 2017

2

1 reference

Europe PubMed Central

15 September 2017

273-279

1 reference

Europe PubMed Central

15 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-008-0120-4

0 references

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Increase in mRNA concentrations of pituitary receptors for growth hormone-releasing hormone and growth hormone secretagogues after neonatal monosodium glutamate treatment

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Prognostic markers in triple-negative breast cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-008-0120-4

Identifiers

10.1007/S10549-008-0120-4

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39961053&oldid=2119256498"